Dec 20, 2024 · Results showed that participants in CagriSema lost 22.7% of their body weight at 68 weeks. Novo in its press announcement called this effect “statistically significant and superior” to cagrilintide and semaglutide, which elicited weight-loss of 11.8% and 16.1% at the same time point, respectively.

1 day ago · Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors question trial protocols and transparency as Novo plans a new study.

Dec 20, 2024 · Results showed that participants in CagriSema lost 22.7% of their body weight at 68 weeks. Novo in its press announcement called this effect “statistically significant and superior” to cagrilintide and semaglutide, which elicited weight-loss of 11.8% and 16.1% at the same time point, respectively.

1 day ago · The relatively low share of participants taking the full dose of CagriSema could explain the lower-than-expected average weight loss. But it’s the hushed nature of the flexible protocol that has ...

Dec 26, 2024 · CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial...

Jan 10, 2025 · CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide 2.4mg and semaglutide 2.4mg) in overweight or obese patients without type 2 diabetes.

Dec 20, 2024 · Despite hitting its primary endpoints, the company’s REDEFINE 1 Phase III trial (NCT05669755) saw patients achieving a weight loss of 22.7% after 68 weeks on CariSema compared to a reduction of 11.8% with cagrilintide 2.4 mg or 16.1% with semaglutide.

Dec 20, 2024 · When applying the treatment policy estimand 2, people treated with CagriSema achieved a superior weight loss of 20.4% compared to a reduction of 11.5% with cagrilintide 2.4 mg, 14.9% with semaglutide 2.4 mg and 3.0% with placebo.

Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...

When applying the treatment policy estimand 2, people treated with CagriSema achieved a superior weight loss of 20.4% compared to a reduction of 11.5% with cagrilintide 2.4 mg, 14.9% with semaglutide 2.4 mg and 3.0% with placebo.